摘要
目的探讨氟西汀联合小剂量奎硫平治疗女性抑郁症的临床疗效及安全性。方法将58例女性抑郁症患者随机分为研究组28例，对照组30例，研究组口服氟西汀联合奎硫平治疗，对照组单用氟西汀治疗，观察8w。于治疗前及治疗1w、2w、4w、8w末采用汉密顿焦虑量表、汉密顿抑郁量表评定临床疗效，副反应量表评定不良反应。结果治疗8w末，研究组显效率为85．71％，对照组为63．33％，研究组显著高于对照组（χ^2=3．968，P〈0．05）；研究组治疗1w末和对照组治疗2w末后各时段汉密顿焦虑量表、汉密顿抑郁量表评分较治疗前均有显著下降（P〈0．01），同期研究组均较对照组下降显著（P〈0．05或0．01）；两组不良反应均轻微，但发生率差异有显著性（P〈0．05）。结论氟西汀联合小剂量奎硫平治疗女性抑郁症疗效肯定，优于单用氟西汀治疗，且起效更快，不良反应轻微，安全性高，能显著提高患者的治疗依从性。
Objective To explore the clinical efficacy and safety of fluoxetine combined with small--dose quetiapine in the treatment of female patients with depression. Methods 58 female depression patients were randomly assigned to research group （n= 28, fluoxetine plus quetiapine） and control group （n= 30, fluoxetine alone） for 8 weeks. Curative effects were assessed with the Hanmilton Anxiety Scale（HAMA） and the Hanmilton Depression Scale（HAMD） and adverse reactions with the Treatment Emergent Symptom Scale（TESS） before treatment and at the ends of the 1^st, 2^nd, 4^th, 8^th week treatment. Results At the end of the 8^th week, effective rates were respectively 85.71% in the research and 63.33% in the control group, the former was significantly higher than the latter（P〈0.05）; compared with pre-treatment, the HAMA and HAMD score lowered more significantly in the research since the end of the 1^st week and in the control group since the end of the 2^nd week （P〈0.01）, and did more significantly in the research than in the control group （P〈0. 05 or 0.01 ）;adverse reactions of both groups were milder, but there was a significant difference in incidence. Conclusion Fluoxetine combined with small-dose quetiapine has positive efficacy,takes effects rapidly, adverse reactions are milder and safety higher and could notably improve patients＇ compliance in the treatment of depression compared with single use of fluoxetine.
出处
《临床心身疾病杂志》
CAS
2009年第1期19-20,52,共3页
Journal of Clinical Psychosomatic Diseases
